BRCA1 and cancer: The most established and successful of these endeavours, thus far, is the development of Poly (ADP-ribose) polymerase (PARP) inhibitors to selectively target BRCA1/2 mutated cancers and other cancers with underlying defects in DNA repair by homologous recombination18–21.